Browse by UCL people
Group by: Type | Date
Jump to: Article
Number of items: 6.
Article
Chen, L;
Esfandiari, A;
Reaves, W;
Vu, A;
Hogarty, MD;
Lunec, J;
Tweddle, DA;
(2018)
Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.
International Journal of Oncology
, 52
(3)
pp. 967-977.
10.3892/ijo.2018.4261.
|
|
Drummond, CJ;
Esfandiari, A;
Liu, J;
Lu, X;
Hutton, C;
Jackson, J;
Bennaceur, K;
... Lunec, J; + view all
(2016)
TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation.
Oncotarget
, 7
(29)
pp. 46203-46218.
10.18632/oncotarget.10073.
|
 |
|
Esfandiari, A;
Hawthorne, TA;
Nakjang, S;
Lunec, J;
(2016)
Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
Molecular Cancer Therapeutics
, 15
(3)
pp. 379-391.
10.1158/1535-7163.MCT-15-0651.
|
|
|
Vena, F;
Jia, R;
Estandian, A;
Garcia-Gomez, JJ;
Rodriguez-Justo, M;
MA, J;
Syed, S;
... Hochhauser, D; + view all
(2018)
MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models.
Oncotarget
, 9
(14)
pp. 11592-11603.
10.18632/oncotarget.24294.
|
|
|
Wu, C-E;
Esfandiari, A;
Ho, Y-H;
Wang, N;
Mahdi, AK;
Aptullahoglu, E;
Lovat, P;
(2018)
Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
British Journal of Cancer
, 118
(4)
pp. 495-508.
10.1038/bjc.2017.433.
|
|
|
Wu, C-E;
Koay, TS;
Esfandiari, A;
Ho, Y-H;
Lovat, P;
Lunec, J;
(2018)
ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma.
Cancers
, 11
(1)
, Article 3. 10.3390/cancers11010003.
|
|
